Laane Edward, Derolf Asa Rangert, Björklund Elisabet, Mazur Joanna, Everaus Hele, Söderhäll Stefan, Björkholm Magnus, Porwit-MacDonald Anna
Department of Pathology and Cytology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden.
Haematologica. 2006 Jun;91(6):833-6.
Minimal residual disease (MRD) levels were determined by multi-parameter flow cytometry in 45 younger adult patients ( pound60 years old) with acute myeloid leukemia (AML) in complete remission. Data were collected after induction (MRD1; n=43) and/or at the end of post-remission chemotherapy or before stem cell transplantation (SCT)(MRD2; n=31). Patients with detectable MRD2 who underwent allogeneic or autologous SCT had significantly better 5-year relapse-free survival than patients not transplanted (80%, 53% and 0%, respectively p=0.003). Therefore allogeneic SCT should be considered in younger adult AML patients with detectable MRD at the end of post-remission chemotherapy. Autologous SCT may be an alternative for patients not eligible for allogeneic SCT.
采用多参数流式细胞术对45例年龄较轻（≤60岁）且处于完全缓解期的急性髓系白血病（AML）成年患者进行微小残留病（MRD）水平检测。在诱导治疗后（MRD1；n = 43）和/或缓解后化疗结束时或干细胞移植（SCT）前（MRD2；n = 31）收集数据。接受异基因或自体SCT且MRD2可检测到的患者5年无复发生存率显著高于未进行移植的患者（分别为80%、53%和0%，p = 0.003）。因此，对于缓解后化疗结束时MRD可检测到的年龄较轻的成年AML患者，应考虑进行异基因SCT。对于不符合异基因SCT条件的患者，自体SCT可能是一种替代方案。
